Article
Microbiology
Jacky Lu, Kanagavel Murugesan, Fiona Senchyna, Indre Budvytiene, Niaz Banaei
Summary: This study evaluated the sensitivity and specificity of QuantiFERON-TB Gold (QFT) in tuberculosis (TB) and non-tuberculous mycobacteria (NTM) patients. The results showed that QFT had a sensitivity of 78.0% in TB patients, with 86.0% in immunocompetent patients and 69.2% in immunocompromised patients. The specificity of QFT in NTM patients was 76.1%, but after excluding NTM patients with risk factors for latent TB infection, the specificity increased to 94.4%.
JOURNAL OF CLINICAL MICROBIOLOGY
(2023)
Article
Medicine, General & Internal
Yeya dit Sadio Sarro, Matthew A. Butzler, Fanta Sanogo, Ousmane Kodio, Mohamed Tolofoudie, Mariam S. Goumane, Bocar Baya, Seydou Diabate, Ibrahim Boubacar Diallo, Djakaridja Daniogo, Bindongo P. P. Dembele, Issiaka Camara, Alisha Kumar, Etienne Dembele, Bourahima Kone, Chad J. Achenbach, Grant Theron, Khadidia Ouattara, Yacouba Toloba, Bassirou Diarra, Seydou Doumbia, Babafemi Taiwo, Jane L. Holl, Robert L. Murphy, Souleymane Diallo, Sally M. McFall, Mamoudou Maiga
Summary: This study evaluated a new Multiplex MTB/NTM assay that can differentiate between MTBC and NTM with high sensitivity and specificity. The assay showed 100% detection rate for MAC at 5 CFUs and demonstrated better specificity than Xpert, enhancing discrimination between TB and NTM infections.
Article
Immunology
Hyewon Lee, Woojae Myung, Eun-Mi Lee, Hyekyeong Kim, Byung Woo Jhun
Summary: NTM-infected patients had a poorer prognosis compared to TB patients or the general population, especially in cases of NTM and TB coinfection. NTM mortality was associated with specific demographic characteristics, but long-term use of macrolides may provide survival benefits.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Dereje A. Negatu, Wassihun Wedajo Aragaw, Julianna Cangialosi, Veronique Dartois, Thomas Dick
Summary: New oxazolidinones are being developed for the treatment of tuberculosis and NTM infections, as a safer alternative to linezolid and tedizolid. This study compared the mitochondrial toxicity and efficacy against mycobacterial pathogens of approved and novel oxazolidinones. The results suggest that TBI-223 and sutezolid show promise for the treatment of tuberculosis and NTM lung disease caused by Mycobacterium kansasii.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Mingxiang Huang, Yaoju Tan, Xuxia Zhang, Yufeng Wang, Biyi Su, Zhongtan Xue, Jingping Wang, Yu Pang
Summary: Through a retrospective study, we found that mixed infections with Mycobacterium tuberculosis (MTB) and nontuberculous mycobacteria (NTM) occurred in approximately 3% of suspected multidrug-resistant tuberculosis (MDR-TB) patients in China, with regional variations. A history of previous TB episodes was correlated with an increased risk of mixed infections.
INFECTION AND DRUG RESISTANCE
(2022)
Review
Microbiology
Caitlin S. Pepperell
Summary: Mycobacterium tuberculosis, a globally distributed lethal pathogen, has developed antiphagocytic defenses and effector systems for adaptation. While losing the ability for lateral gene transfer, it retains the adaptability characteristic of mycobacteria. Studies of its evolution have provided important insights into the formation of new pathogens.
ANNUAL REVIEW OF MICROBIOLOGY
(2022)
Article
Infectious Diseases
Yu He, Jun-Li Wang, Yan-An Zhang, Mao-Shui Wang
Summary: This study analyzed the prevalence of NTM disease and the occurrence of tuberculosis (TB) in patients with positive mycobacterial cultures. The results showed that 8.0% of patients with NTM disease were also diagnosed with TB. Therefore, caution should be taken during the treatment of NTM disease.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Infectious Diseases
Danping Liu, Ling Gu, Renfang Zhang, Li Liu, Yinzhong Shen, Yueming Shao, Jiangrong Wang, Jianjun Sun, Tangkai Qi, Zhenyan Wang, Yang Tang, Wei Song, Jingna Xun, Hongzhou Lu, Jun Chen
Summary: This study investigated the utility of the urine lipoarabinomannan (LAM) test in diagnosing tuberculosis (TB) among hospitalized HIV-positive patients. The results showed that the sensitivity and specificity of the LAM test for TB diagnosis were relatively low, and cross-reactivity with non-tuberculous mycobacteria (NTM) could lead to false-positive results. Therefore, accurate identification of mycobacteria species is important for determining treatment strategies when diagnosing TB.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Critical Care Medicine
Noeul Kang, Kyeongman Jeon, Hojoong Kim, O. Jung Kwon, Hee Jae Huh, Nam Yong Lee, Charles L. Daley, Won-Jung Koh, Byung Woo Jhun
Summary: Treatment with inhaled amikacin-containing regimens shows favorable outcomes in patients with M massiliense-PD, while more effective treatments are needed for those with M abscessus-PD. Overall, 65% of treatment-naive patients achieved cure after 12 months of treatment initiation, with significantly greater improvement observed in patients with M massiliense-PD.
Article
Critical Care Medicine
Sarah A. R. Siegel, David E. Griffith, Julie V. Philley, Barbara A. Brown-Elliott, Amanda E. Brunton, Peter E. Sullivan, Cristina Fuss, Luke Strnad, Richard J. Wallace Jr, Kevin L. Winthrop
Summary: ALIS can lead to sputum culture conversion in half of the patients with macrolide-resistant M abscessus. However, the emergence of mutational amikacin resistance is common and associated with clofazimine monotherapy.
Article
Microbiology
Yoshifumi Uwamino, Akio Aono, Yu Tomita, Kozo Morimoto, Masahiro Kawashima, Hirofumi Kamata, Yuka Sasaki, Hideaki Nagai, Naoki Hasegawa, Satoshi Mitarai
Summary: The Myco-Panel test accurately detects clinically common mycobacterial species that cause respiratory infections, providing useful information for patient management and rapid treatment initiation.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
Stephen Adonai Leon-Icaza, Salimata Bagayoko, Romain Verge, Nino Iakobachvili, Chloe Ferrand, Talip Aydogan, Celia Bernard, Angelique Sanchez Dafun, Marlene Murris-Espin, Julien Mazieres, Pierre Jean Bordignon, Serge Mazeres, Pascale Bernes-Lasserre, Victoria Rame, Jean-Michel Lagarde, Julien Marcoux, Marie-Pierre Bousquet, Christian Chalut, Christophe Guilhot, Hans Clevers, Peter J. Peters, Virginie Molle, Geanncarlo Lugo-Villarino, Kaymeuang Cam, Laurence Berry, Etienne Meunier, Celine Cougoule
Summary: Although Mabs infection can induce oxidative stress, pharmacological activation of antioxidant pathways can better control Mabs growth and reduce its virulence. Genetic and pharmacological inhibition of CFTR is associated with improved Mabs growth and increased virulence. Pharmacological activation of antioxidant pathways can inhibit Mabs growth and improve efficacy when combined with cefoxitin.
Article
Biotechnology & Applied Microbiology
Mohammad Hashemzadeh, Aram Asarehzadegan Dezfuli, Azar Dokht Khosravi, Maryam Moradi Bandbal, Atousa Ghorbani, Mahtab Hamed, Soolmaz Khandan Dezfuli
Summary: This study aimed to investigate the distribution of non-tuberculous mycobacteria (NTM) strains isolated from extrapulmonary (EP) samples in Southwest Iran. Out of 325 suspected EP samples, 77 (62%) were positive for NTM by culture and sequence analysis. M. fortuitum was the most commonly isolated NTM species. Specific programs and resources are needed to improve diagnosis and management of EPNTM infections in Iran.
Article
Microbiology
Bing Li, Liyun Xu, Qi Guo, Jianhui Chen, Yanan Zhang, Wenpan Huang, Zhemin Zhang, Lizhong Han, Xiaogang Xu, Haiqing Chu
Summary: In this study, a new platform called GenSeizer was developed for the rapid and accurate identification of major pathogenic Mycobacterium species causing human diseases, as well as detection of resistance genotypes. The platform showed high specificity and sensitivity with no cross-reactivity, and was able to correctly identify resistance genotypes in blind comparisons and whole-genome sequencing data. This indicates that GenSeizer is an efficient and reliable tool for detecting major pathogenic Mycobacterium species.
JOURNAL OF CLINICAL MICROBIOLOGY
(2021)
Article
Infectious Diseases
Sorasak Intorasoot, Amornrat Intorasoot, Arocha Tawteamwong, Bordin Butr-Indr, Ponrut Phunpae, Chayada Sitthidet Tharinjaroen, Usanee Wattananandkul, Sirikwan Sangboonruang, Jiaranai Khantipongse
Summary: D-hLF 1-11 exhibits antimycobacterial activity against drug-sensitive and drug-resistant Mycobacterium tuberculosis strains, showing potential as a novel treatment option for tuberculosis infections in the future.
